3692
Pending Latest rating：Hold
Entry zone
30.71 – 31.38
Near market · as of 2026-10-15
Stop
29.36
initial distance -6.5%
Full size
10.0%
in tranches 40% / 30% / 30%
Support / resistance
31.36 / 33.2
ATR(14) 1.35
CloseEntry zoneStop
Triggers
- ArmedFirst tranche: price enters the entry zone4.0%@ 31.38
- ArmedAdd 1: pullback holds support (confirmed at close, executed next open)3.0%@ 31.69
- FrozenAdd 2: breakout above resistance on volume, held 2 days3.0%@ 33.2
- ArmedStop: sell everything below this price@ 29.36
Timeline
- Rating change · Buy → Hold
- Entered pool@ 31.38
Rating historyChinese only
- Hold现价高于 30.71–31.38 的入场区间约 10%，不追；等回落到 31 附近
- Hold下调——单日放量 +8.3%，已脱离候补区间 30.71–31.38 约 10%，不追高，等回踩 32 附近
- BuyBD 授权收入兑现中、净利率 42%，现价略高于候补入场区 30.71–31.38，回踩分批，止损 29.36
- Buy候补池标的（10-16 入池，入场区间 30.71–31.38，止损 29.36），评级与上次一致为买入；90.5% 毛利率 + 对外授权管线是"中国创新药 BD 1200 亿美元"这条主线最稳健的载体；现价略高于入场区间上沿，回踩 31.38 以内执行
- Buy未变；收盘略高于入场上沿 31.38，回踩区间内分批；它同时是再生元 GLP-1 管线的供给方，产业链位置独特
- Buy维持——候补区间 30.71–31.38 刚上方，PE 25 倍对应净利 +40%，港股创新药里估值与增速最匹配的，止损 29.36
- BuyPE 24 + 净利 +40% + ESMO 催化，是本组估值与增长匹配度最好的；二元风险：ESMO 数据不及预期
Earlier rounds
| In | Out | Entry | P&L | R | Exit reason |
|---|---|---|---|---|---|
| 2026-09-15 | 2026-10-09 | 34.4 | -6.9% | -1.02 | Stop loss |
Paper portfolio executed mechanically from published rules. Not real trades, not investment advice.